Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9628MR)

This product GTTS-WQ9628MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9628MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11070MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ10054MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ8666MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ9421MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ2782MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ12332MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ6990MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ETI-204
GTTS-WQ3126MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA APN311
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW